$815 Mn Viral Vector Manufacturing Market - Global Forecast to 2023 - Ongoing Research Into Viral Vector-Based Gene and Cell Therapies Driving the Market
DUBLIN, Aug. 15, 2018 /PRNewswire/ --
The "Viral Vector Manufacturing Market by Type, Disease, Application, End User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The global viral vector manufacturing market is projected to reach USD 815.8 million by 2023 from USD 327.8 million in 2018, at a CAGR of 20.0%.
Some key factors driving market growth include the rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies. Untapped potential in emerging markets is expected to offer lucrative growth opportunities for players in the market.
In this report, the global market is segmented by type, disease, application, end user. By type, the market is segmented into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors. The adeno-associated viral vector manufacturing segment is expected to grow at the highest CAGR during the forecast period as they have applications in most cell-based gene therapies.
Based on disease, the market is segmented into cancer, genetic disorders, infectious diseases, and other diseases. In 2018, cancer is expected to account for the largest share of the global market. Its large share can be attributed to growing research on viral vector gene therapies for cancer.
By application, the viral vector manufacturing market is segmented into gene therapy and vaccinology. The gene therapy segment is expected to grow at the highest rate during the forecast period. The availability of effective viral vector gene therapies for rare diseases and cancers, ongoing research activities on viral vector gene therapies, and the recent approval of several viral vector gene therapies are driving the growth of this market.
Based on end users, the viral vector manufacturing market is segmented into pharmaceutical and biopharmaceutical companies and research institutes. In 2018, pharmaceutical and biopharmaceutical companies are expected to account for the largest share of the global market. The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the key factors contributing to the growth of the pharmaceutical and biopharmaceutical companies segment during the forecast period.
Geographically, Asia Pacific is expected to grow at the fastest rate viral vector manufacturing market during the forecast period. The fast growth of this regional segment can be attributed to the growing research activities to launch novel gene therapies in the untapped markets of this region.
While the overall market is expected to grow during the forecast period, the high price of gene therapies and short shelf-life of viral vectors are likely to restrain the growth of this market to a certain extent. The major players in the global market include Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US).
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Market Overview
5 Market Overview
5.1 Introduction
5.2 Evolution
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
5.3.1.2 Availability of Funding for the Development of Gene Therapy
5.3.1.3 Effectiveness of Viral Vectors
5.3.1.4 Ongoing Research Into Viral Vector-Based Gene and Cell Therapies
5.3.2 Restraints
5.3.2.1 High Costs Associated With Gene Therapy
5.3.2.2 Short Shelf-Life of Viral Vectors
5.3.3 Challenges
5.3.3.1 Risk of Mutagenesis and Other Unwanted Outcomes
6 Viral Vector Manufacturing Market, By Type
6.1 Introduction
6.2 Retroviral Vectors
6.2.1 Lentiviral Vectors
6.2.2 Gamma-Retroviral Vectors
6.3 Adenoviral Vectors
6.4 Adeno-Associated Viral Vectors
6.5 Other Viral Vectors
7 Viral Vector Manufacturing Market, By Disease
7.1 Introduction
7.2 Cancer
7.3 Genetic Disorders
7.4 Infectious Diseases
7.5 Other Diseases
8 Viral Vector Manufacturing Market, By Application
8.1 Introduction
8.2 Gene Therapy
8.3 Vaccinology
9 Viral Vector Manufacturing Market, By End User
9.1 Introduction
9.2 Pharmaceutical and Biopharmaceutical Companies
9.3 Research Institutes
10 Viral Vector Manufacturing Market, By Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia Pacific
10.5 Rest of the World
11 Competitive Landscape
11.1 Overview
11.1.1 Product Approval
11.1.2 Collaborations, Partnerships, and Agreements
11.1.3 Acquisitions and Mergers
11.1.4 Expansions
12 Company Profiles
12.1 Lonza
12.2 Merck KGaA
12.3 Oxford Biomedica
12.4 Cobra Biologics
12.5 Novasep
12.6 Spark Therapeutics
12.7 Kaneka Eurogentec
12.8 Finvector Vision Therapies
12.9 Brammer Bio
12.10 Cell and Gene Therapy Catapult (CGT Catapult)
12.11 Fujifilm Holdings Corporation
12.12 Uniqure
12.13 Regenxbio
12.14 Massbiologics
For more information about this report visit https://www.researchandmarkets.com/research/g9z4m9/815_mn_viral?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
